Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Med Mycol. 2010 Mar;48(2):263–272. doi: 10.1080/13693780903081976

FIG 3. Activity of CAP37 peptides against fluconazole-sensitive and -resistant isolates of C. albicans blastoconidia.

FIG 3

Activity of the four CAP37 peptides, CAP3720-44 (20-44), CAP3720-44Ser26 (Ser 26), CAP3720-44Ser42 (Ser 42), and CAP3720-44Ser26/42 (Ser 26/42) at 400 μg/ml (solid bars) and 200 μg/ml (diagonal striped bars) was evaluated against blastoconidia from three clinical isolates of Candida albicans known to be fluconazole-sensitive (a–c) and three isolates known to be fluconazole-resistant (d–e). The percent inhibition is determined as detailed in the Materials and Methods section. Values are expressed as ± standard error of the mean from three independent experiments performed in triplicate. *P <0.05 and ***P <0.001 compared to activity with control peptide, CAP3720-44ser26/42 at 400 μg/ml and #P<0.05 compared to activity with control peptide at 200 μg/ml using ANOVA followed by Dunnett’s Multiple Comparison Test.